erlotinib hydrochloride

Phase 3

UUniversity of Texas Southwestern Medical Center

erlotinib hydrochloride is one of 7 therapeutic programs targeting Cirrhosis, Liver. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Cirrhosis, LiverNot yet recruiting

Lung Non-Squamous Non-Small Cell CarcinomaActive, not recruiting

Adult Solid NeoplasmActive, not recruiting

Cirrhosis, LiverPhase 2

Not yet recruiting

Lung Non-Squamous Non-Small Cell CarcinomaPhase 3

Active, not recruiting

Adult Solid NeoplasmPhase 1

Active, not recruiting

Competition

Competitive Landscape

5 competitors in Lung Non-Squamous Non-Small Cell Carcinoma

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 3

1 2

Paraplatin

AAvyxa

Phase 3

1 3

Tarceva

OOSI Pharmaceuticals

Phase 3

1 4

Alimta

SShawn Eagle

Phase 3

1 5

Alimta

EEagle Pharmaceuticals, Inc.

Phase 3

1 6

erlotinib hydrochloride

UUniversity of Texas Southwestern Medical Center

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 3Active, not recruiting

Lung Non-Squamous Non-Small Cell Carcinoma

NCT02193282

Phase 1Active, not recruiting

Adult Solid Neoplasm

NCT00878163

Phase 1Active, not recruiting

Metastatic Pancreatic Adenocarcinoma

NCT01660971

Phase 2Active, not recruiting

Recurrent Lung Non-Small Cell Carcinoma

NCT01708954

Q3 2027

Phase 1Active, not recruiting

Adult Solid Neoplasm

NCT00045201

Q3 2030

Phase 2Not yet recruiting

Cirrhosis, Liver

NCT04172779

Clinical

Trials by Indication[1]

Adult Solid Neoplasm2 trials

Phase I Trial of the Combination of Vismodegib GDC-0449 and Erlotinib +/- Gemcitabine

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT00878163·55 enrolled

Phase I Trial of OSI-774 and CPT-11 in Patients With Advanced Solid Tumors

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT00045201·60 enrolled

Metastatic Pancreatic Adenocarcinoma1 trial

A Phase 1 Study of Gemcitabine, Dasatinib and Erlotinib in Patients With Advanced Pancreatic Carcinoma

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT01660971·19 enrolled

Recurrent Lung Non-Small Cell Carcinoma1 trial

A Randomized Phase II Trial of Erlotinib, Cabozantinib, or Erlotinib Plus Cabozantinib as 2nd or 3rd Line Therapy in Patients With EGFR Wild-Type NSCLC

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT01708954·125 enrolled

Lung Non-Squamous Non-Small Cell Carcinoma1 trial

Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT02193282·390 enrolled

Cirrhosis, Liver1 trial

Phase II Clinical Trial of Low-dose Erlotinib for Hepatocellular Carcinoma Chemoprevention

Not yet recruiting·UUniversity of Texas Southwestern Medical Center·Phase 2·NCT04172779·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for erlotinib hydrochloride. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for erlotinib hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — University of Texas Southwestern Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: UUniversity of Texas Southwestern Medical Center

erlotinib hydrochloride

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q3 2027

Q3 2030

Trials by Indication[1]

Adult Solid Neoplasm2 trials

Metastatic Pancreatic Adenocarcinoma1 trial

Recurrent Lung Non-Small Cell Carcinoma1 trial

Lung Non-Squamous Non-Small Cell Carcinoma1 trial

Cirrhosis, Liver1 trial

References

Drug Info

Quick Facts

Related News